RG7112

A potent and selective inhibitor of p53-MDM2 interaction; binds MDM2 with high affinity (Kd=11 nM) ; stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts. orally bioactive. (In Vitro) :RG7112 (0-5 μM) stabilizes wild-type p53 and induces p53 signaling in cancer cells. RG7112 effectively activates p53 functions in cancer cells. (In Vivo) :RG7112 (25-200 mg/kg, single oral dose) activates p53 pathway and induces apoptosis in tumor cells in vivo.RG7112 (100 mg/kg, gavage once per day, 5 days/week for 3 weeks) reduces tumor growth rate and increases survival in GBM models.

Product Specifications

CAS Number

939981-39-2

Product Name Alternative

RG-7112 | RG 7112

Purity

>98% (HPLC)

Solubility

10 mM in DMSO

Smiles

CCOC1=C (C=CC (=C1) C (C) (C) C) C2=NC (C (N2C (=O) N3CCN (CC3) CCCS (=O) (=O) C) (C) C4=CC=C (C=C4) Cl) (C) C5=CC=C (C=C5) Cl

Molecular Formula

C38H48Cl2N4O4S

Molecular Weight

727.7831

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

Methanone, [ (4S,5R) -4,5-bis (4-chlorophenyl) -2-[4- (1,1-dimethylethyl) -2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3- (methylsulfonyl) propyl]-1-piperazinyl]-